Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer Talks Up Phase III Pipeline To Offset Lipitor Pain

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Pharma giant expects to have 24 to 28 programs in Phase III development by the end of 2009, representing a 50 percent to 70 percent increase, management says during an analyst day March 5. Pain and oncology are key disease areas Pfizer will focus on going forward. Investors, however, were unimpressed with the show

You may also be interested in...

Pfizer’s IGF-1 Inhibitor Leads Pack In Phase III For NSCLC

Pfizer's CP-751,871 for metastatic non-small cell lung cancer recently became the first insulin-like growth factor 1 receptor inhibitor to enter Phase III trials, as the class gains popularity and strength

Krystal Sees Success With Topical Gene Therapy In Debilitating Rare Skin Disorder

A regulatory filing for Vyjuvek in the US is targeted for the first half of 2022 following the positive results of a Phase III trial, positioning Krystal for its first commercial launch.

J&J's Next Immunology Act Centers On Nipocalimab For Autoantibody-Driven Diseases

The company has ramped up a broad R&D program for the FcRn inhibitor in 11 autoantibody-driven disease areas.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts